Your Article Summary
Ustekinumab: Treatment of Adult Moderate-to-Severe Chronic Plaque Psoriasis
Annals of Pharmacotherapy, 08/12/09
Scanlon JV et al. – Ustekinumab, a promising new therapy, reduces the extent and severity of psoriasis and was well tolerated in clinical trials. Ongoing clinical trials will allow clinicians to further assess the efficacy/safety profile of this novel biologic.
Related Articles
Pediatric psoriasis: an update
Therapeutics and Clinical Risk Management, 10/22/09
Relevance Score: 95%
FDA Approves New Drug to Treat Psoriasis
Internet Source, 11/02/09
Relevance Score: 91%
Study shows major burden of psoriasis
Internet Source, 10/29/09
Relevance Score: 91%
Prevalence of myocardial infarction in patients with psoriasis in central China
Journal of the European Academy of Dermatology and Venereology, 10/27/09
Relevance Score: 91%
Why nail psoriasis remains difficult to treat
Dermatology in Practice, 10/12/09
Relevance Score: 91%
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Oral ondansetron for reducing vomiting secondary to acute gastroenteritis in children – a double-blind randomized study
Alimentary Pharmacology and Therapeutics, 12/04/09
The Unintended Consequences of Clinical Trials Regulations
PLoS Medicine, 12/04/09
Characterization of Baseline Methicillin-Resistant Staphylococcus aureus Isolates Recovered from Phase IV Clinical Trial for Linezolid
Journal of Clinical Microbiology, 12/03/09
Article Search
Sponsor


See Latest Articles


